Compare CFLT & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CFLT | PRAX |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.7B | 8.8B |
| IPO Year | 2021 | 2020 |
| Metric | CFLT | PRAX |
|---|---|---|
| Price | $30.57 | $307.97 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 31 | 13 |
| Target Price | $29.40 | ★ $397.85 |
| AVG Volume (30 Days) | ★ 8.6M | 600.5K |
| Earning Date | 02-11-2026 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,113,149,000.00 | $7,463,000.00 |
| Revenue This Year | $22.76 | N/A |
| Revenue Next Year | $16.57 | $14,827.76 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 21.57 | ★ 364.98 |
| 52 Week Low | $15.64 | $26.70 |
| 52 Week High | $37.90 | $326.91 |
| Indicator | CFLT | PRAX |
|---|---|---|
| Relative Strength Index (RSI) | 75.46 | 61.83 |
| Support Level | $30.42 | $266.93 |
| Resistance Level | $30.63 | $326.83 |
| Average True Range (ATR) | 0.09 | 19.27 |
| MACD | -0.20 | -0.68 |
| Stochastic Oscillator | 88.89 | 75.79 |
Confluent Inc provides a data streaming platform that enables customers to connect their applications, systems, and data layers and can be deployed as a fully managed cloud-native software-as-a-service (SaaS) offering. Its products include Confluent Cloud, a self-managed software offering, Confluent Platform, a managed service offering where the raw data resides inside a customer's cloud environment, and WarpStream, among others. Confluent also offers professional services and education services. The company generates revenue from the sale of subscriptions and services. Geographically, it generates a majority of its revenue from its business in the United States and the rest from International markets.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.